VYNE Therapeutics (VYNE) investor reports 5.5M-share, 16.5% ownership stake

Rhea-AI Filing Summary

VYNE Therapeutics Inc. has a large shareholder, Zhang Xiaofan, who reports beneficial ownership of 5,511,558 shares of VYNE common stock, par value $0.0001 per share. This represents 16.5% of the outstanding common stock.

Zhang Xiaofan, a citizen of Hong Kong with an address in Shanghai, reports sole voting power and sole dispositive power over all 5,511,558 shares and no shared voting or dispositive power.

Key Figures

Shares Beneficially Owned: 5,511,558 shares Percent of Class: 16.5% Par Value per Share: $0.0001 +1 more

4 metrics

Shares Beneficially Owned 5,511,558 shares Common stock of VYNE Therapeutics Inc. beneficially owned by Zhang Xiaofan

Percent of Class 16.5% Portion of VYNE common stock class beneficially owned by Zhang Xiaofan

Par Value per Share $0.0001 Par value of VYNE Therapeutics Inc. common stock

CUSIP 92941V308 CUSIP number for VYNE Therapeutics Inc. common stock

Key Terms

beneficially owned, Sole power to vote, Sole power to dispose, Percent of class

4 terms

beneficially owned financial

"Item 4. | Ownership (a) | Amount beneficially owned: 5511558"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole power to vote regulatory

"(i) Sole power to vote or to direct the vote: 5511558"

Sole power to dispose regulatory

"(iii) Sole power to dispose or to direct the disposition of: 5511558"

Percent of class financial

"(b) | Percent of class: 16.5%"

Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/17/2026 - 09:54 AM Accepted by SEC EDGAR 07/17/2026 - 09:54 AM Learn about SEC filing dates

FAQ

What percentage of VYNE (VYNE) does Zhang Xiaofan report owning?

Zhang Xiaofan reports beneficial ownership of 16.5% of VYNE Therapeutics Inc.’s common stock, representing 5,511,558 shares. This ownership stake is reported with sole voting and sole dispositive power over all of the shares.

How many VYNE (VYNE) shares does Zhang Xiaofan beneficially own?

Zhang Xiaofan beneficially owns 5,511,558 shares of VYNE Therapeutics Inc. common stock. These shares represent 16.5% of the class and are held with sole power to vote and sole power to dispose, with no shared authority reported.

Does Zhang Xiaofan have sole or shared voting power over VYNE (VYNE) shares?

Zhang Xiaofan reports sole voting power over 5,511,558 shares of VYNE common stock. No shared voting power is indicated, and the same number of shares is held with sole dispositive power and no shared dispositive authority.

What is the class of securities reported in this VYNE (VYNE) Schedule 13G/A?

The securities are common stock of VYNE Therapeutics Inc., with a par value of $0.0001 per share. The filing also identifies the security by CUSIP number 92941V308, confirming the specific class being reported.

Where is the reporting person in the VYNE (VYNE) Schedule 13G/A based and what is the citizenship?

The reporting person, Zhang Xiaofan, lists a principal address in Shanghai and reports citizenship as Hong Kong. This information helps identify the holder of the 5,511,558 shares of VYNE common stock reported in the filing.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

VYNE Therapeutics Inc.

(Name of Issuer)

common stock, par value $0.0001

(Title of Class of Securities)

92941V308

(CUSIP Number)

06/08/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 92941V308

1

Names of Reporting Persons

Zhang Xiaofan

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power
6	Shared Voting Power
7	Sole Dispositive Power
8	Shared Dispositive Power

9

Aggregate Amount Beneficially Owned by Each Reporting Person

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

12

Type of Reporting Person (See Instructions)

SCHEDULE 13G

Item 1.
(a)	Name of issuer: VYNE Therapeutics Inc.
(b)	Address of issuer's principal executive offices: 685 ROUTE 202/206 N., SUITE 301, 685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER, NEW JERSEY, 08807.
Item 2.
(a)	Name of person filing: zhang xiaofan
(b)	Address or principal business office or, if none, residence: Rm1607, tower 3, central residence, 1038 Huashan Road, Shanghai
(c)	Citizenship: Hong Kong
(d)	Title of class of securities: common stock, par value $0.0001
(e)	CUSIP No.: 92941V308
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 5511558
(b)	Percent of class: 16.5%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 5511558
	(ii) Shared power to vote or to direct the vote:
	(iii) Sole power to dispose or to direct the disposition of: 5511558
	(iv) Shared power to dispose or to direct the disposition of:
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Zhang Xiaofan

Signature:	zhang xiaofan
Name/Title:	Mr
Date:	07/17/2026